{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:01:06Z","timestamp":1787004066083,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81230013, 81370666"],"award-info":[{"award-number":["81230013, 81370666"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Municipal Science and Technology Program","award":["Z141100000214011 and Z151100001615020"],"award-info":[{"award-number":["Z141100000214011 and Z151100001615020"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.bbmt.2016.03.012","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T18:27:17Z","timestamp":1458152837000},"page":"1080-1086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Lan-Ping","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.03.012_bib1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.03.012_bib2","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib4","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.25092","article-title":"Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I","volume":"116","author":"Velev","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.03.012_bib5","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib6","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.03.012_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbmt.2016.03.012_bib8","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.03.012_bib9","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.03.012_bib10","first-page":"1590","article-title":"Chronic myelogenous leukemia, version 1.2015","volume":"12","author":"O'Brien","year":"2014","journal-title":"JNCCN"},{"key":"10.1016\/j.bbmt.2016.03.012_bib11","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","article-title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib12","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib13","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","article-title":"Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation","volume":"107","author":"Lu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib14","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.27761","article-title":"Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in\u00a0vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.03.012_bib15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/07853890801908903","article-title":"HLA-mismatched\/haploidentical hematopoietic stem cell transplantation without in\u00a0vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase","volume":"40","author":"Xiao-Jun","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.bbmt.2016.03.012_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical hematopoietic stem cell transplantation without in\u00a0vitro T-cell depletion for the treatment of hematological malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.012_bib17","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.bbmt.2015.06.014","article-title":"Interferon-alpha: a potentially effective treatment for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Mo","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.012_bib18","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","article-title":"Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?","volume":"37","author":"Qin","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.03.012_bib20","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib21","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.012_bib22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.012_bib23","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib24","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/bmt.2014.146","article-title":"Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis","volume":"49","author":"Jiang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.012_bib25","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.03.012_bib26","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V97.6.1560","article-title":"Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"97","author":"Olavarria","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.03.012_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbmt.2010.07.023","article-title":"Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia","volume":"17","author":"Huang","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.012_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bmt.1705734","article-title":"Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor","volume":"40","author":"Chim","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.012_bib29","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.leukres.2009.02.020","article-title":"Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoietic stem cell transplantation with donor lymphocyte transfusion and interferon-alpha-2b","volume":"33","author":"Wang","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.03.012_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbmt.2006.09.005","article-title":"Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience","volume":"13","author":"Arellano","year":"2007","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116001610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116001610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:55:20Z","timestamp":1761058520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116001610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1083879116001610"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}